文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

铁死亡和铁代谢特征可准确预测肝细胞癌的临床诊断、预后和免疫微环境。

The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma.

机构信息

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Hospital, School of Medicine, Zhejiang University, Lishui, 323000, China.

Department of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China.

出版信息

Cell Commun Signal. 2020 Oct 28;18(1):174. doi: 10.1186/s12964-020-00663-1.

DOI:10.1186/s12964-020-00663-1
PMID:33115468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7592541/
Abstract

BACKGROUND: In this study, we comprehensively analyzed genes related to ferroptosis and iron metabolism to construct diagnostic and prognostic models and explore the relationship with the immune microenvironment in HCC. METHODS: Integrated analysis, cox regression and the least absolute shrinkage and selection operator (LASSO) method of 104 ferroptosis- and iron metabolism-related genes and HCC-related RNA sequencing were performed to identify HCC-related ferroptosis and iron metabolism genes. RESULTS: Four genes (ABCB6, FLVCR1, SLC48A1 and SLC7A11) were identified to construct prognostic and diagnostic models. Poorer overall survival (OS) was exhibited in the high-risk group than that in the low-risk group in both the training cohort (P < 0.001, HR = 0.27) and test cohort (P < 0.001, HR = 0.27). The diagnostic models successfully distinguished HCC from normal samples and proliferative nodule samples. Compared with low-risk groups, high-risk groups had higher TMB; higher fractions of macrophages, follicular helper T cells, memory B cells, and neutrophils; and exhibited higher expression of CD83, B7H3, OX40 and CD134L. As an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy. CONCLUSIONS: The prognostic and diagnostic models based on the four genes indicated superior diagnostic and predictive performance, indicating new possibilities for individualized treatment of HCC patients. Video Abstract.

摘要

背景：本研究综合分析与铁死亡和铁代谢相关的基因，构建诊断和预后模型，并探讨其与肝癌免疫微环境的关系。

方法：通过对 104 个铁死亡和铁代谢相关基因和 HCC 相关 RNA 测序的综合分析、Cox 回归和最小绝对值收缩和选择算子（LASSO）方法，鉴定与 HCC 相关的铁死亡和铁代谢基因。

结果：鉴定出 4 个基因（ABCB6、FLVCR1、SLC48A1 和 SLC7A11）构建预后和诊断模型。在训练队列（P<0.001，HR=0.27）和测试队列（P<0.001，HR=0.27）中，高风险组的总生存期（OS）均明显差于低风险组。诊断模型成功区分了 HCC 与正常样本和增生结节样本。与低风险组相比，高风险组的 TMB 更高；巨噬细胞、滤泡辅助 T 细胞、记忆 B 细胞和中性粒细胞的分数更高；CD83、B7H3、OX40 和 CD134L 的表达更高。作为铁死亡的诱导剂，依维莫司抑制 HCC 细胞增殖和进展，通过生物信息学分析表明其通过影响 Th17 细胞分化和 IL-17 信号通路，提示其可能是癌症免疫治疗的潜在药物。

结论：基于这 4 个基因的预后和诊断模型具有较好的诊断和预测性能，为 HCC 患者的个体化治疗提供了新的可能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/e90dd35734d0/12964_2020_663_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/60cec154e0ac/12964_2020_663_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/6f4e27a77dc4/12964_2020_663_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/fff832d066bf/12964_2020_663_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/06d7db5bc88b/12964_2020_663_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/4674154ab134/12964_2020_663_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/0807ca8acecd/12964_2020_663_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/21d47ba8793f/12964_2020_663_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/e2f8d2c6f80d/12964_2020_663_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/01534b88a803/12964_2020_663_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/17b4edcacfa3/12964_2020_663_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/e91b7835900e/12964_2020_663_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/e90dd35734d0/12964_2020_663_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/60cec154e0ac/12964_2020_663_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/6f4e27a77dc4/12964_2020_663_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/fff832d066bf/12964_2020_663_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/06d7db5bc88b/12964_2020_663_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/4674154ab134/12964_2020_663_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/0807ca8acecd/12964_2020_663_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/21d47ba8793f/12964_2020_663_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/e2f8d2c6f80d/12964_2020_663_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/01534b88a803/12964_2020_663_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/17b4edcacfa3/12964_2020_663_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/e91b7835900e/12964_2020_663_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bb4/7592541/e90dd35734d0/12964_2020_663_Fig12_HTML.jpg

相似文献

[1]
The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma.

Cell Commun Signal. 2020-10-28

[2]
A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.

Front Immunol. 2022

[3]
Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.

Front Immunol. 2021

[4]
Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.

BMC Cancer. 2022-3-2

[5]
A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma.

J Cell Mol Med. 2021-7

[6]
Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.

Front Immunol. 2024

[7]
Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma.

J Cancer Res Clin Oncol. 2024-6-19

[8]
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.

World J Gastroenterol. 2020-1-14

[9]
Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.

Int J Med Sci. 2021

[10]
A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma.

Adv Clin Exp Med. 2022-10

引用本文的文献

[1]
Iron and Cancer.

Adv Exp Med Biol. 2025

[2]
Downregulation of ferroptosis-related Genes can regulate the invasion and migration of osteosarcoma cells.

Sci Rep. 2025-5-21

[3]
A novel prognostic framework for HBV-infected hepatocellular carcinoma: insights from ferroptosis and iron metabolism proteomics.

Brief Bioinform. 2025-5-1

[4]
Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis.

Cancer Cell Int. 2025-3-26

[5]
Design of self-assembled micelles based on natural dual-targeting strategies and evaluation of their anti-liver cancer effects as drug delivery systems.

NPJ Precis Oncol. 2025-3-22

[6]
Exploring the Role of Metabolic Hyperferritinaemia (MHF) in Steatotic Liver Disease (SLD) and Hepatocellular Carcinoma (HCC).

Cancers (Basel). 2025-2-28

[7]
Iron and siRNA co-encapsulated ferritin nanocages induce ferroptosis synergistically for cancer therapy.

Acta Pharm Sin B. 2025-1

[8]
Targeting Ferroptosis in Rare Neurological Disorders Including Pediatric Conditions: Innovations and Therapeutic Challenges.

Biomedicines. 2025-1-22

[9]
Development and validation of a prognostic model based on disulfidptosis-related ferroptosis genes: and as biomarkers for predicting prognosis in colon cancer.

Transl Cancer Res. 2025-1-31

[10]
WTAP regulates Mitochondrial damage and Lipid oxidation in HCC by NOA1 mediated m6A modification.

J Cancer. 2025-1-1

本文引用的文献

[1]
Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo.

PLoS One. 2019-12-4

[2]
Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11.

Cancer Discov. 2019-9-25

[3]
Tumor mutation burden: from comprehensive mutational screening to the clinic.

Cancer Cell Int. 2019-8-7

[4]
Pan-cancer analysis of iron metabolic landscape across the Cancer Genome Atlas.

J Cell Physiol. 2019-6-25

[5]
Engineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer.

ACS Nano. 2019-5-6

[6]
CD8 T cells regulate tumour ferroptosis during cancer immunotherapy.

Nature. 2019-5-1

[7]
Update on hepatocellular carcinoma: Pathologists' review.

World J Gastroenterol. 2019-4-14

[8]
Iron metabolism and its contribution to cancer (Review).

Int J Oncol. 2019-2-20

[9]
The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11.

Cancer Res. 2019-2-1

[10]
Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma.

Onco Targets Ther. 2019-1-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索